Hemogenyx Pharmaceuticals Share Discussion Threads

[runwaypaul] 28/2/2018 12:41

will be interesting to see the results of mice tests summer 2019.

bit of a wait, but could be worth it.gl

[tsmith2] 28/2/2018 11:52

Sells dried up..next leg up me thinks, primed

[ernestsyngen] 28/2/2018 11:51

This could be a huge Multibagger this year. If confirmation of a big player coming in is announced then this will pay the mortgage

[cottoner] 28/2/2018 09:00

runwaypaul28 Feb '18 - 08:08 - 341 of 345

page 8

2015

2016

No mention of

First data results have shown that CDX bi-specific antibodies are capable of attacking and eliminating the blood cancer Acute Myelogenous Leukemia (AML) in vitro. Using these new humanised mice the Company is confident that it should be able to demonstrate that its lead product, CDX bi-specific antibodies, are effective in the treatment of (AML).

[andrbea] 28/2/2018 08:51

i reckon that hemo should be at 10p and imm at 200p
it's just dilly-dallying till we finally get there.

imm and hemo are the best pharam stories going.

[tsmith2] 28/2/2018 08:46

v v little stock

[goodbloke1] 28/2/2018 08:16

You bought back then? What price?

[runwaypaul] 28/2/2018 08:08

page 8

2015

2016

[runwaypaul] 28/2/2018 08:07

says it here



cant see how this is new news?

[tsmith2] 28/2/2018 07:58

now you are talking b*llcks..I hold both and think both potentially offer exceptional multi baggers

[jimmyhoffa262] 28/2/2018 07:22

Think I'll wait for sub 3.5p entry it's coming

[sidjameslaugh] 28/2/2018 07:08

I’m sure that was yesterday’s prediction:)

[cottoner] 28/2/2018 06:30

Where in the IPO document does it say?

'First data results have shown that CDX bi-specific antibodies are capable of attacking and eliminating the blood cancer Acute Myelogenous Leukemia (AML) in vitro. Using these new humanised mice the Company is confident that it should be able to demonstrate that its lead product, CDX bi-specific antibodies, are effective in the treatment of (AML).'


As the HEMO CEO stated in the RNS

Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx, commented: "We are hugely excited by the first solid data that we've received testing the efficacy of CDX antibodies against Acute Myelogenous Leukemia. The results which show that they can attack and eliminate AML cells is a true breakthrough and a significant development in our process of developing CDX to become a universally available conditioning product for patients undergoing bone marrow transplants as a treatment for serious blood diseases.

[runwaypaul] 27/2/2018 23:31

Maybe they were retweeting.....

[runwaypaul] 27/2/2018 23:30

This news appears to have been mentioned in the ipo document.it was released in 2016?

[ernestsyngen] 27/2/2018 21:37

Going to be a bagger all year

[purple11] 27/2/2018 20:13

a lot of noise as expected.Mr Holden embarrassing himself as he often does! hopefully some managed to trade it successfully/enjoyed the rise.atb

RNS EXCLUSIVE: HemoGenyx release successful CDX Antibody first data results

[ny boy] 27/2/2018 16:49

Will add some more tomorrow if the market allows me a good price.

[tsmith2] 27/2/2018 16:47

Long auctions

[sidjameslaugh] 27/2/2018 16:32

Consigned as another forgotten share collecting more long term holders along the way.

[the stigologist] 27/2/2018 15:54

Yes VRS could easily be 1000p within the next year

[lufc5] 27/2/2018 15:45

Stig. At least VRS looks to be on the turn.